How Kyverna rode CAR T’s autoimmune wave to the FDA’s door

Poised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.